Inventor
Eugene D. Thorsett
Inventor
Moss Beach, CA, US
Overview
Patents· 107 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
C07DHeterocyclic compounds26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C07KPeptides14%
C07CAcyclic or carbocyclic compounds7%
Y02ATechnologies for adaptation to climate change4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
C12NMicroorganisms or enzymes0%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture0%
C12RIndexing scheme associated with subclasses c12c - c12q, relating to microorganisms0%
PatentTitleYear
7,973,044'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20117,968,547'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20117,745,454'Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4'20107,635,775'Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists'20097,538,215'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20097,468,365'Lactam compound'20087,452,912'Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4'20087,427,628'Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins'20087,390,801'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds'20087,378,529'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20087,365,073'3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4'20087,335,663'Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins'20087,320,960'Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4'20087,291,645'Phenylalanine derivatives as alpha 4 integrin inhibitors'20077,288,526'Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4'20077,229,970'Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4'20077,223,762'Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4'20077,183,281'Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists'20077,166,580'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20077,135,477'Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins'20067,115,768'Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4'20067,101,855'Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4'20067,074,783'Sulfonylbenzodiazepinone acetamides as bradykinin antagonists'20067,056,937'Sulfonylquinoxalone derivatives as bradykinin antagonists'20067,053,220'Hydroxyalkanoyl aminopyrazoles and related compounds'20067,049,306'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4.'20067,030,114'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20067,026,328'Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins'20067,015,216'Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors'20067,008,949'Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins'20067,005,433'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20066,974,829'Succinoyl aminopyrazoles and related compounds'20056,953,802'Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4'20056,951,854'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds'20056,949,570'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20056,911,439'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20056,903,088'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20056,900,179'Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4'20056,888,022'Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis'20056,861,558'Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis'20056,849,650'Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds'20056,803,370'Alpha amino acid derivativesinhibitors of leukocyte adhesion mediated by VLA-4'20046,794,506'3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4'20046,767,918'N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20046,689,781'Phenylalanine derivatives as alpha 4 integrin inhibitors'20046,683,075'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use'20046,667,305'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,653,303'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,642,261'N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,635,632'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,632,811'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,586,602'Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4'20036,583,139'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20036,579,867'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,559,127'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20036,559,141'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,545,160'aminocetic acid derivatives- 47 receptor antagonists'20036,544,978'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,545,003'Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4'20036,541,466'Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,525,026'Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4'20036,518,424'Substituted pyrimidine compositions and methods of use'20036,506,782'Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20036,495,693'N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same, and methods for inhibiting -amyloid peptide release and/or its synthesis by use of such compounds'20026,492,421'Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,492,372'Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,489,300'Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,479,492'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,476,263'Compounds for inhibiting -amyloid peptide release and/or its synthesis'20026,465,513'Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,436,904'Compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,423,688'Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,410,781'-aminoacetic acid derivatives-47 receptor antagonists'20026,407,066'Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,399,628'N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds'20026,362,341'Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4'20026,333,351'N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds'20016,313,152'N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds'20016,291,453'4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4'20016,211,235'Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis'20016,207,710'Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis'20016,191,166'Methods and compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis'20016,117,901'N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use'20006,096,782'N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds'20006,001,809'Inhibitors of leukocyte adhesion'19995,994,398'Arylsulfonamides as phospholipase A.sub.2 inhibitors'19995,965,614'N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds'19995,484,940'Substituted 3-indolyl-5-pyrazolone compounds'19965,384,309'Cyclized peptides and their use as platelet aggregation inhibitors'19955,247,074'(2-substituted phenyl) carbapenems'19935,037,820'Carbapenem antibacterial agents'19914,921,857'4-Oxo-4h-quinolizine-3-carboxylic acids and derivatives thereof'19904,873,235'Benzofused lactams as antihypertensives'19894,680,392'Substituted caprolactam derivatives as antihypertensives'19874,661,479'Bicyclic lactams as antihypertensives'19874,634,715'Aza analogs of carboxyalkyl dipeptide derivatives as antihypertensives'19874,629,787'Substituted caprolactam derivatives as antihypertensives'19864,609,742'Difficol, intermediate in antibiotic preparation'19864,594,341'Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives as antihypertensives'19864,587,238'Substituted caprylolactam derivatives as anti-hypertensives'19864,587,050'Substituted enantholactam derivatives as antihypertensives'19864,520,021'Substituted caprolactam derivatives as antihypertensives'19854,415,496'Bicyclic lactams'19834,409,146'Substituted caprolactam derivatives as antihypertensives'19834,396,616'Substituted enantholactam derivatives as antihypertensives'19834,379,146'Substituted phosphonamides as antihypertensives'19834,316,896'Aminoacid derivatives as antihypertensives'1982Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1982–1993Patents assigned to MERCK & CO INC (18)· patent assignee history
1982–1990Based in Fanwood, NJ, US· patent location history
1991–2008Based in Moss Beach, CA, US· patent location history
1996Based in South San Francisco, CA, US· patent location history
1999–2011Patents assigned to ELAN PHARM INC (40)· patent assignee history
1999–2008Patents assigned to ATHENA NEUROSCIENCES INC (26)· patent assignee history
2000–2008Patents assigned to LILLY CO ELI (28)· patent assignee history
2002–2010Based in Half Moon Bay, CA, US· patent location history
2004–2011Patents assigned to WYETH CORP (24)· patent assignee history
2006–2011Based in Kirkland, WA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ELAN PHARM INC | 40 | 1999–2011 |
| LILLY CO ELI | 28 | 2000–2008 |
| ATHENA NEUROSCIENCES INC | 26 | 1999–2008 |
| WYETH CORP | 24 | 2004–2011 |
| MERCK & CO INC | 18 | 1982–1993 |
Locations
| Location | Patents | Span |
|---|---|---|
| Moss Beach, California, US | 53 | 1991–2008 |
| Half Moon Bay, California, US | 27 | 2002–2010 |
| Fanwood, New Jersey, US | 16 | 1982–1990 |
| Kirkland, Washington, US | 10 | 2006–2011 |
| South San Francisco, California, US | 1 | 1996 |